EGFR and neoplasm: After nearly 8 weeks of oral administration of the third-generation EGFR-TKI aumolertinib (110 mg/day) started in February 2021, imaging showed significant tumor regression, lesion volume reduction to 2.2 × 2.0 × 1.8 cm, partial remission (PR), and clinical stage reduction to stage IB (T2N0M0).